Venous Leg Ulcer Market Set to Evolve with Advancements in Wound Care and Rising Patient Burden by 2034 | Says DelveInsight

Venous Leg Ulcer (VLU), the most common chronic lower limb ulcer, presents major clinical and economic challenges, especially in older adults and those with venous insufficiency. DelveInsight's report highlights how venous hypertension and valve dysfunction lead to non-healing ulcers, while improved diagnostics and awareness enable earlier detection and better management.
DelveInsight's " [https://www.delveinsight.com/report-store/venous-leg-ulcer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]" provides a comprehensive analysis of the VLU landscape, including detailed historical and projected epidemiological data across major markets such as the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report also outlines the current standard of care, unmet needs, evolving treatment patterns, and the pipeline of emerging therapies targeting wound healing and venous restoration.

With the introduction of advanced wound care solutions, compression technologies, and bioengineered skin substitutes, the VLU market is poised for significant innovation and expansion. This report offers critical insights into market dynamics, key growth drivers, and the pharmaceutical and medical device companies leading the charge in transforming VLU care. It serves as a valuable resource for industry stakeholders, investors, researchers, and clinicians aiming to navigate the evolving VLU treatment ecosystem.

Some of the Key Facts of the Venous Leg Ulcer Market Report:

- The venous leg ulcer market is expected to grow at a significant CAGR by 2034.

- In 2023, the US had the highest number of diagnosed VLU cases among the 7MM, with numbers expected to rise by 2034.

- VLU affected more women than men in the US, a trend likely to continue during the forecast period.

- Older adults in the US showed the highest age-specific prevalence of VLU.

- Among EU4 and the UK, Germany had the most VLU cases, while Spain had the fewest.

- Overall, men were less affected by VLU than women in 2023.

- VLU treatment includes wound care, compression therapy, medications, and advanced therapies.

- Surgical options and adjunctive treatments like HBOT and NPWT are used for chronic cases.

- In May 2025, MediWound Ltd. (Nasdaq: MDWD) announced the publication of a peer-reviewed post hoc analysis in Wounds. The analysis draws on data from the company's Phase II ChronEx clinical trial, which evaluated the safety and efficacy of EscharEx Registered in treating venous leg ulcers (VLUs) compared to collagenase ointment (SANTYL Registered ), currently the only FDA-cleared enzymatic debridement agent available for dermal ulcers.

- In February 2025, MediWound Ltd. (Nasdaq: MDWD) announced the launch of VALUE, a pivotal global Phase III trial to evaluate EscharEx Registered for treating venous leg ulcers (VLUs).

- In December 2024, Merakris Therapeutics announced the start of enrollment for Part 2 of its Phase 2 trial (NCT04647240) testing Dermacyte Registered Amniotic Wound Care Liquid. This randomized, double-blind, placebo-controlled study will enroll patients at approximately 10 US sites, with dosing beginning promptly. The injectable biologic is designed to aid healing in venous leg ulcers (VLUs).

- In September 2024, Merakris Therapeutics announced FDA approval to begin Part 2 of its Phase II clinical trial (NCT04647240) for Dermacyte Registered Amniotic Wound Care Liquid, a subcutaneous biological injection, after reviewing initial study results.

- In February 2024, MediWound announced positive results from a head-to-head comparison of EscharEx versus SANTYL within the ChronEx Phase II Randomized Controlled Study. The results demonstrated the superiority of EscharEx, a bromelain-based gel, over SANTYL, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients with chronic venous leg ulcers (VLU).

- Leading companies in the venous leg ulcer market include Reponex Pharmaceuticals, Energenesis Biomedical, MediWound, Solascure Limited, TR Therapeutics, Promore Pharma AB, NovaLead Pharma, RHEACELL, and others.

- Emerging acute venous leg ulcer drugs include rhGM-CSF, ENERGI-F703, EscharEx, Aurase Registered Wound Gel, TR 987, Ropocamptide, NLP328, APZ 2, and others.

- The increasing prevalence of venous leg ulcers and ongoing advancements in therapeutic options are driving the demand for more effective treatment approaches.

To know in detail about the venous leg ulcer market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Venous Leg Ulcer Market Forecast [https://www.delveinsight.com/report-store/venous-leg-ulcer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Venous Leg Ulcer Overview

Venous Leg Ulcers (VLUs) are chronic, non-healing wounds that typically occur on the lower legs due to chronic venous insufficiency (CVI). They represent the most common type of leg ulcer and are a major health burden, especially in aging populations. VLUs are primarily caused by elevated venous pressure resulting from valve dysfunction in the leg veins, leading to blood pooling, inflammation, and eventual skin breakdown.

Clinically, VLUs present as shallow, irregularly shaped wounds, often located around the medial malleolus, with symptoms such as swelling, aching, and skin discoloration. They are often recurrent and slow to heal, significantly impairing patients' quality of life.

Management of VLUs involves a multifaceted approach, including compression therapy (the cornerstone of treatment), wound care, pharmacologic agents, and in some cases, surgical or endovascular interventions. Despite available treatments, healing can be slow, and recurrence rates remain high, emphasizing the need for innovative therapies and personalized care.

Recent advancements in biologics, enzymatic debridement agents, and adjunctive treatments such as negative pressure wound therapy (NPWT) and hyperbaric oxygen therapy (HBOT) are reshaping the treatment landscape. With growing awareness and better diagnostic tools, early intervention and improved outcomes are becoming increasingly achievable.

Get a free sample of the Venous Leg Ulcer market report with key insights and emerging therapies here: https://www.delveinsight.com/report-store/venous-leg-ulcer-market [https://www.delveinsight.com/report-store/venous-leg-ulcer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Venous Leg Ulcer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Venous Leg Ulcer Epidemiology Segmentation:

The venous leg ulcer epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:

- Total Prevalent Cases of VLU

- Gender-Specific Cases of VLU

- VLU cases by severity/ chronicity of wound

- Total Diagnosed Cases of VLU

- Age-Specific Cases of VLU

- Treated cases of VLU

Download the report to understand which factors are driving venous leg ulcer epidemiology trends @ Venous Leg Ulcer Epidemiology Forecast [https://www.delveinsight.com/report-store/venous-leg-ulcer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Venous Leg Ulcer Drugs Uptake and Pipeline Development Activities

The venous leg ulcer drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the venous leg ulcer market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug.

Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share.

The report further delves into the venous leg ulcer pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies.

Venous Leg Ulcer Market Strengths

- The increasing incidence of chronic venous insufficiency, particularly among the elderly, is driving demand for effective VLU treatments.

- Innovations such as bioengineered dressings, negative pressure wound therapy (NPWT), and digital health tools are enhancing treatment efficacy and patient outcomes.

Venous Leg Ulcer Market Weaknesses

- High Treatment Costs: Advanced therapies and wound care products can be expensive, limiting accessibility, especially in low-income regions.

- Limited Awareness and Diagnosis: A lack of awareness among patients and healthcare providers can lead to delayed diagnosis and suboptimal treatment, hindering market growth.

Scope of the Venous Leg Ulcer Market Report

- Study Period: 2020-2034

- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

- Key Venous Leg Ulcer Companies: Reponex Pharmaceuticals, Energenesis Biomedical, MediWound, Solascure Limited, TR Therapeutics, Promore Pharma AB, NovaLead Pharma, RHEACELL, and others.

- Key Venous Leg Ulcer Therapies: rhGM-CSF, ENERGI-F703, EscharEx, Aurase Registered Wound Gel, TR 987, Ropocamptide, NLP328, APZ 2, and others.

- Venous Leg Ulcer Therapeutic Assessment: Venous leg ulcer, currently marketed, and Venous Leg Ulcer emerging therapies

- Venous Leg Ulcer Market Dynamics: Venous leg ulcer market drivers and Venous Leg Ulcer market barriers

- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

- Venous Leg Ulcer Unmet Needs, KOL's views, Analyst's views, Venous Leg Ulcer Market Access and Reimbursement

To learn more about the key players and advancements in the venous leg ulcer treatment landscape, visit the Venous Leg Ulcer Market Analysis Report [https://www.delveinsight.com/report-store/venous-leg-ulcer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Table of Contents

1. Venous Leg Ulcer Market Report Introduction

2. Executive Summary for Venous Leg Ulcer

3. SWOT analysis of Venous Leg Ulcer

4. Venous Leg Ulcer Patient Share (%) Overview at a Glance

5. Venous Leg Ulcer Market Overview at a Glance

6. Venous Leg Ulcer Disease Background and Overview

7. Venous Leg Ulcer Epidemiology and Patient Population

8. Country-Specific Patient Population of Venous Leg Ulcer

9. Venous Leg Ulcer Current Treatment and Medical Practices

10. Venous Leg Ulcer Unmet Needs

11. Venous Leg Ulcer Emerging Therapies

12. Venous Leg Ulcer Market Outlook

13. Country-Wise Venous Leg Ulcer Market Analysis (2020-2034)

14. Venous Leg Ulcer Market Access and Reimbursement of Therapies

15. Venous Leg Ulcer Market Drivers

16. Venous Leg Ulcer Market Barriers

17. Venous Leg Ulcer Appendix

18. Venous Leg Ulcer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=venous-leg-ulcer-market-set-to-evolve-with-advancements-in-wound-care-and-rising-patient-burden-by-2034-says-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.